Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06162468 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Feasibility Trial of EUS-PCA in IPMN Pancreatic Cysts

StatusNot Yet Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated April 23, 2025 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Start date: Mar 31, 2025 to May 31, 2025v4
  2. Primary completion date: Jun 30, 2025 to Jun 30, 2026
    • Start date: Jun 2024 to Mar 31, 2025
    • Study completion date: Aug 31, 2025 to Jul 31, 2026
    v3
  3. Primary completion date: Dec 31, 2024 to Jun 30, 2025
    • Start date: Mar 2024 to Jun 2024
    • Study completion date: Dec 31, 2024 to Aug 31, 2025
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this single-arm intervention trial is to determine the feasibility of implementing endoscopic ultrasound-guided pancreatic cyst chemoablation (EUS-PCA) using gemcitabine and paclitaxel for intraductal papillary mucinous neoplasms (IPMN) in two New Zealand tertiary interventional endoscopy centres.
Trial Details
NCT Number NCT06162468
Lead Sponsor University of Auckland, New Zealand
Collaborators: Gut Cancer Foundation, New Zealand, North Shore Hospital, New Zealand, Waikato Hospital
Conditions
(from sponsor)		 Intraductal Papillary Mucinous Neoplasm of Pancreas
Related terms Pancreatic Intraductal Neoplasms
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov